U-BX Technology Announces Direct Securities Offering
- Securities Purchase Agreement: U-BX Technology has entered into a securities purchase agreement with several investors to sell securities at a price of $0.30 per Unit, with expected gross proceeds of approximately $4.55 million, which will support the company's operational and capital needs.
- Unit Composition: Each Unit consists of one Class A ordinary share and a warrant to purchase 0.3 of a Class A ordinary share, a structure that not only attracts investor interest but also provides flexibility for future financing opportunities.
- Underwriter Arrangement: FT Global Capital, Inc. is acting as the exclusive placement agent, while Kingswood Capital Partners, LLC serves as co-placement agent, ensuring professionalism and market recognition for the offering, which is expected to close around April 29, 2026.
- Registration Statement Validity: The offering is conducted under an effective F-3 registration statement filed with the SEC on December 15, 2025, reflecting the company's commitment to compliance and transparency, which helps enhance investor confidence.
Trade with 70% Backtested Accuracy
Analyst Views on UBXG
About UBXG
About the author

- Reverse Split Implementation: U-BX Technology announced a 1-for-25 reverse stock split effective May 22, reducing Class A shares from approximately 37.79 million to about 1.51 million and Class B shares from about 7.66 million to around 0.31 million, aimed at increasing share price to attract more investors.
- Shareholder Approval Range: At the annual meeting in November 2025, shareholders approved a reverse stock split range of 1-for-2 to 1-for-250, with the final ratio determined by the board on May 12, demonstrating the company's responsiveness to shareholder input and market conditions.
- Trading Adjustment: Following the reverse split, Class A shares will begin trading on a split-adjusted basis under the existing ticker symbol “UBXG” on May 22, which is expected to enhance the company's image and liquidity in the capital markets.
- Shareholder Rights Protection: U-BX Technology stated that no fractional shares will be issued, with shareholders entitled to fractional shares receiving one full share instead, ensuring all shareholders' rights are protected and fostering trust in the company.
- Reverse Stock Split Decision: U-BX Technology Ltd. has announced a 1-for-25 reverse stock split aimed at enhancing stock liquidity and attracting more investor interest, which is expected to positively impact the company's market capitalization.
- Shareholder Meeting Approval: At the shareholder meeting on November 4, 2025, shareholders approved the reverse stock split proposal, granting the board the authority to determine the exact split ratio, reflecting confidence in the company's future growth.
- Significant Reduction in Shares: Following the reverse split, U-BX's class A ordinary shares will decrease from approximately 37.79 million to about 1.51 million, while class B shares will drop from around 7.66 million to approximately 0.31 million, significantly increasing earnings per share and net asset value per share.
- Trading Adjustment Date: U-BX's class A ordinary shares will begin trading on an adjusted basis on May 22, 2026, with the new CUSIP number G9161K120, ensuring a smooth transition for investors to the new capital structure.
- Securities Purchase Agreement: U-BX Technology has entered into a securities purchase agreement with several investors to sell securities at a price of $0.30 per Unit, with expected gross proceeds of approximately $4.55 million, which will support the company's operational and capital needs.
- Unit Composition: Each Unit consists of one Class A ordinary share and a warrant to purchase 0.3 of a Class A ordinary share, a structure that not only attracts investor interest but also provides flexibility for future financing opportunities.
- Underwriter Arrangement: FT Global Capital, Inc. is acting as the exclusive placement agent, while Kingswood Capital Partners, LLC serves as co-placement agent, ensuring professionalism and market recognition for the offering, which is expected to close around April 29, 2026.
- Registration Statement Validity: The offering is conducted under an effective F-3 registration statement filed with the SEC on December 15, 2025, reflecting the company's commitment to compliance and transparency, which helps enhance investor confidence.

Edgewise Therapeutics Surge: Shares of Edgewise Therapeutics, Inc. rose 26.5% in pre-market trading after positive Phase 2 trial results for Sevasemten in Becker muscular dystrophy patients.
Market Movements: Several stocks saw significant pre-market gains, including Sidus Space (59.4%) and PureTech Health (22.8%), while Akoustis Technologies faced a sharp decline of 39.8% following a Chapter 11 filing.
Trading Halt: U-BX Technology (UBXG) Ltd has had its trading halted due to pending news, with updates expected soon.
Recent Developments: The company has recently announced a 1-for-16 reverse stock split and has been addressing compliance issues with Nasdaq.
U-BX Technology Ltd. Compliance Notification: U-BX Technology Ltd. received notifications from Nasdaq indicating that it has not met the minimum closing bid price and market value requirements for continued listing, but it has been granted a 180-day compliance period until April 21, 2025, to rectify these issues.
Company Overview and Services: U-BX is an insurance technology provider in China that offers AI-driven services such as digital promotion, risk assessment through its "Magic Mirror" algorithm, and bundled benefits for insurance carriers.








